News Leqembi sales grow again after subcutaneous approvals Biogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.
News Altimmune alcohol use disorder drug hits the mark in phase 2 Altimmune's pemvidutide has been shown to reduce drinking in people with alcohol use disorder, adding to the evidence for GLP-1 drugs in this setting.
News EU first to clear AbbVie's Rinvoq for alopecia areata AbbVie's fast-growing JAK inhibitor Rinvoq has been cleared for alopecia areata in the EU, its first market for the hair loss disorder.
News US judge says Novo Nordisk must face lawsuit over CagriSema A US judge has ruled that Novo Nordisk must face a lawsuit claiming it defrauded investors with misleading statements about a pivotal CagriSema study.
News GSK to quit Stevenage for new R&D site in Cambridge In a major shake-up of its UK operations, GSK is building a brand new R&D centre in Cambridge and transfer operations there from its Stevenage campus.
News HIV resurgence looming as international aid declines More than 3m people worldwide could be infected with HIV by the end of the decade following a steep fall in international aid funding, says UNAIDS.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.